Clinical trial
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
NCT00395421 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00395421 |
|---|---|
| Title | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin |
| Official title | A Partially-blinded, Randomized, Parallel-group Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between Valopicitabine and Ribavirin When Administered in Combination With Pegylated Interferon Alfa-2a in Treatment-naive Patients With Chronic Hepatitis C |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | NM283 plus Peg-IFNα-2a |
| Enrollment | 114 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Nov 2, 2006 |
| Last update posted | Jun 10, 2010 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: